文献速递头颈部肿瘤放疗

热疗联合挽救性同步放化疗治疗既往放疗后不可切除复发头颈癌的II期试验

Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated patients.
PubMed 文献 · Radiat Oncol · 2025-02-08

这项单臂II期试验评估热疗加入挽救性同步放化疗对既往放疗后不可切除复发头颈癌的疗效与安全性。35例患者接受50 Gy/22次放疗、每周热疗6次及每周顺铂联合多西他赛化疗。总缓解率82.9%,中位总生存32.8个月,中位无进展生存14.9个月,毒性可控。

要点

  • 35例可评估患者总缓解率82.9%,完全缓解54.3%。
  • 中位随访2.7年,中位总生存32.8个月,2年总生存57.1%。
  • 中位无进展生存14.9个月,2年无进展生存34.3%。

核心结论

  • 在既往放疗后不可切除复发头颈癌中,挽救性同步放化疗加入热疗相比历史再照射结局大幅提高肿瘤缓解率和生存率,毒性可控。

研究设计与样本

  • 单臂II期临床试验,纳入35例既往接受过放疗且不适合挽救手术的非转移性复发头颈癌患者。
  • 放疗为先对大体积肿瘤区加量10 Gy/2次,再对临床靶区40 Gy/20次,总量50 Gy/22次。
  • 热疗从放疗开始后每周1次共6次,每次40分钟,于放疗后2小时内开始,最高温度维持42±0.5°C。
  • 同步化疗为每周顺铂20 mg/m2和多西他赛10-12 mg/m2,共6周。
  • 主要终点为总缓解率,同时评估总生存、无进展生存和毒性。

主要发现

  • 总缓解率82.9%,其中完全缓解54.3%、部分缓解28.6%、疾病稳定11.4%、疾病进展5.7%。
  • 中位随访2.7年,中位总生存32.8个月(95%CI 16.7-48.9),2年总生存57.1%(95%CI 40.6-73.6)。
  • 中位无进展生存14.9个月(95%CI 5.7-24.1),2年无进展生存34.3%(95%CI 18.6-50.0)。
  • 急性黏膜炎0-1级68.6%、2级25.7%、3级5.7%;急性皮炎0-1级85.7%、2级14.3%。
  • 无明确烧伤发生;3-4级白细胞减少14.3%、贫血14.3%、血小板减少8.6%;12例骨坏死;无5级毒性。

关键数值与推荐

  • 放疗总量50 Gy/22次,先大体积肿瘤区10 Gy/2次加量,再临床靶区40 Gy/20次。
  • 热疗每周1次共6次,每次40分钟,放疗后2小时内开始,最高温度42±0.5°C。
  • 同步化疗每周顺铂20 mg/m2和多西他赛10-12 mg/m2,共6周。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: This single-arm phase II trial aimed to assess the effectiveness and safety of incorporating hyperthermia into salvage concurrent chemoradiotherapy (CCRT) for previously irradiated unresectable recurrent head and neck cancer. METHODS: We enrolled patients with non-metastatic recurrent head and neck cancer who had previously undergone radiotherapy (RT) and were unfit for salvage surgery. Eligible patients received hyperthermia during salvage CCRT. RT consisted of an upfront boost with 10 Gy in 2 fractions to gross tumor volume, followed by 40 Gy in 20 fractions to clinical target volume, for a total of 50 Gy in 22 fractions. Weekly hyperthermia for 6 sessions started after RT initiation; each session lasted for 40 min, beginning within 2 h after RT and maintaining a maximum temperature of 42 ± 0.5 °C. Concurrent chemotherapy included weekly cisplatin 20 mg/m2 and docetaxel 10-12 mg/m2 for 6 weeks. Primary endpoint was overall response rate (ORR). Overall survival (OS), progression-free survival (PFS) and toxicities were evaluated. RESULTS: Among 35 eligible patients, ORR was 82.9%, with complete response in 54.3%, partial response in 28.6%, stable disease in 11.4%, and progressive disease in 5.7%. After a median follow-up of 2.7 years, median OS was 32.8 months (95% confidence interval [CI], 16.7-48.9), and 2-year OS was 57.1% (95% CI, 40.6-73.6). Median PFS was 14.9 months (95% CI, 5.7-24.1), and 2-year PFS was 34.3% (95% CI, 18.6-50.0). Acute mucositis was grade 0-1 in 68.6%, grade 2 in 25.7%, and grade 3 in 5.7%. Acute dermatitis was grade 0-1 in 85.7% and grade 2 in 14.3%. No definite burn injury occurred. Grade 3-4 leucopenia, anemia, thrombocytopenia accounted for 14.3%, 14.3%, and 8.6%, respectively. Osteonecrosis was noted in 12 patients. No grade 5 toxicity was observed. CONCLUSIONS: Adding hyperthermia to salvage CCRT greatly enhances tumor response and survival rates compared to historical re-irradiation outcomes for previously irradiated unresectable recurrent head and neck cancer, with manageable toxicities. TRIAL REGISTRATION: ClinicalTrials.gov (Identifier: NCT02567383 ), Registered October 1 , 201 5 - https://www. CLINICALTRIALS: gov/study/NCT02567383.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Yang KL, Chi MS, Hao CY, et al. Phase II clinical trial assessing the addition of hyperthermia to salvage concurrent chemoradiotherapy for unresectable recurrent head and neck cancer in previously irradiated patients. Radiat Oncol. 2025. PMID: 39920700. doi:10.1186/s13014-025-02585-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。